The Experts below are selected from a list of 4800 Experts worldwide ranked by ideXlab platform

Jerzy Samochowiec - One of the best experts on this subject based on the ideXlab platform.

  • pharmacogenetics of adverse events in Schizophrenia treatment comparison study of ziprasidone olanzapine and perazine
    European Psychiatry, 2015
    Co-Authors: Piotr Tybura, B Trzesniowskadrukala, Jerzy Samochowiec
    Abstract:

    The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in Paranoid Schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. Methods One hundred ninety-one Polish patients suffering from Paranoid Schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms) was measured at baseline and after 12 weeks of antipsychotic treatment. Results After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of extrapyramidal symptoms. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. Conclusion The selected polymorphisms are not primarily involved in changes in body weights and extrapyramidal symptoms related to antipsychotic treatment in Paranoid Schizophrenia patients.

  • pharmacogenetics of adverse events in Schizophrenia treatment comparison study of ziprasidone olanzapine and perazine
    Psychiatry Research-neuroimaging, 2014
    Co-Authors: Piotr Tybura, Beata Trześniowskadrukala, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec
    Abstract:

    The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in Paranoid Schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from Paranoid Schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in Paranoid Schizophrenia patients.

  • p03 119 pharmacogenetic studies of olanzapine perazine and ziprasidone in Paranoid Schizophrenia
    European Psychiatry, 2010
    Co-Authors: Jerzy Samochowiec, Piotr Tybura, Dorota Frydecka, Aleksander Beszlej
    Abstract:

    Literature data revealed that efficacy and side effects of antipsychotic treatment are influenced by multiple genes interactions. Polymorphic variation is likely to contribute substantially in this matter. Pharmacogenetic studies will help to determine which drug and dosage are best for each individual patient. The aim of our study was to find: 1. Genetic markers influencing susceptibility of Paranoid Schizophrenia. The polymorphisms of DRD2 (-141C del/ins, Taq1A, egzon8), DAT, 5HT2a, 5HTT_LPR, COMT, MAO A and GRIK3 genes were studied. 2. Relationships between different gene variants and the treatment efficacy measured by the PANSS. The group of 201 patients with Paranoid Schizophrenia consisted of 95 men (mean age 34) and 105 women (mean age 35). There were no significant differences between the groups according to the studied gender. Males patients had a significantly earlier age of onset but the duration of illness was similar in both gender groups. The patients were treated randomly with perazine, olanzapine or ziprasidone. The control group consist of 230 healthy volunteers ethnically, gender and age matched. Results 1. No differences were found in the allelic distribution in the investigated genes polymorphisms between the whole schizophrenics and the control group. 2. Associations between DAT: A9 allele, DRD2: del 141C allele, DRD2: Taq1A A1 allele, COMT: Met/Met genotype, MAOA: 4VNTR allel (males only) and GRIK3: SER allel with non responding patients were found.

Piotr Tybura - One of the best experts on this subject based on the ideXlab platform.

  • pharmacogenetics of adverse events in Schizophrenia treatment comparison study of ziprasidone olanzapine and perazine
    European Psychiatry, 2015
    Co-Authors: Piotr Tybura, B Trzesniowskadrukala, Jerzy Samochowiec
    Abstract:

    The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in Paranoid Schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. Methods One hundred ninety-one Polish patients suffering from Paranoid Schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms) was measured at baseline and after 12 weeks of antipsychotic treatment. Results After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of extrapyramidal symptoms. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. Conclusion The selected polymorphisms are not primarily involved in changes in body weights and extrapyramidal symptoms related to antipsychotic treatment in Paranoid Schizophrenia patients.

  • pharmacogenetics of adverse events in Schizophrenia treatment comparison study of ziprasidone olanzapine and perazine
    Psychiatry Research-neuroimaging, 2014
    Co-Authors: Piotr Tybura, Beata Trześniowskadrukala, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec
    Abstract:

    The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in Paranoid Schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from Paranoid Schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in Paranoid Schizophrenia patients.

  • p03 119 pharmacogenetic studies of olanzapine perazine and ziprasidone in Paranoid Schizophrenia
    European Psychiatry, 2010
    Co-Authors: Jerzy Samochowiec, Piotr Tybura, Dorota Frydecka, Aleksander Beszlej
    Abstract:

    Literature data revealed that efficacy and side effects of antipsychotic treatment are influenced by multiple genes interactions. Polymorphic variation is likely to contribute substantially in this matter. Pharmacogenetic studies will help to determine which drug and dosage are best for each individual patient. The aim of our study was to find: 1. Genetic markers influencing susceptibility of Paranoid Schizophrenia. The polymorphisms of DRD2 (-141C del/ins, Taq1A, egzon8), DAT, 5HT2a, 5HTT_LPR, COMT, MAO A and GRIK3 genes were studied. 2. Relationships between different gene variants and the treatment efficacy measured by the PANSS. The group of 201 patients with Paranoid Schizophrenia consisted of 95 men (mean age 34) and 105 women (mean age 35). There were no significant differences between the groups according to the studied gender. Males patients had a significantly earlier age of onset but the duration of illness was similar in both gender groups. The patients were treated randomly with perazine, olanzapine or ziprasidone. The control group consist of 230 healthy volunteers ethnically, gender and age matched. Results 1. No differences were found in the allelic distribution in the investigated genes polymorphisms between the whole schizophrenics and the control group. 2. Associations between DAT: A9 allele, DRD2: del 141C allele, DRD2: Taq1A A1 allele, COMT: Met/Met genotype, MAOA: 4VNTR allel (males only) and GRIK3: SER allel with non responding patients were found.

G B Leong - One of the best experts on this subject based on the ideXlab platform.

  • the capgras syndrome in Paranoid Schizophrenia
    Psychopathology, 1992
    Co-Authors: J A Silva, G B Leong
    Abstract:

    Capgras syndrome is characterized by a delusion of impostors who are thought to be physically similar but psychologically distinct from the misidentified person. This syndrome is generally thought to be relatively rare. Most of our knowledge about Capgras syndrome derives from single case studies and small series of cases usually from diagnostically heterogeneous groups. In this article, a series of 31 patients suffering from both Paranoid Schizophrenia and Capgras syndrome is described. Issues pertaining to the phenomenology of Capgras syndrome, the possible relation between Capgras syndrome and other delusional misidentification syndromes, and a neurobiological hypothesis aimed at explaining Capgras syndrome are discussed.

Aleksander Beszlej - One of the best experts on this subject based on the ideXlab platform.

  • pharmacogenetics of adverse events in Schizophrenia treatment comparison study of ziprasidone olanzapine and perazine
    Psychiatry Research-neuroimaging, 2014
    Co-Authors: Piotr Tybura, Beata Trześniowskadrukala, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec
    Abstract:

    The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in Paranoid Schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from Paranoid Schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in Paranoid Schizophrenia patients.

  • p03 119 pharmacogenetic studies of olanzapine perazine and ziprasidone in Paranoid Schizophrenia
    European Psychiatry, 2010
    Co-Authors: Jerzy Samochowiec, Piotr Tybura, Dorota Frydecka, Aleksander Beszlej
    Abstract:

    Literature data revealed that efficacy and side effects of antipsychotic treatment are influenced by multiple genes interactions. Polymorphic variation is likely to contribute substantially in this matter. Pharmacogenetic studies will help to determine which drug and dosage are best for each individual patient. The aim of our study was to find: 1. Genetic markers influencing susceptibility of Paranoid Schizophrenia. The polymorphisms of DRD2 (-141C del/ins, Taq1A, egzon8), DAT, 5HT2a, 5HTT_LPR, COMT, MAO A and GRIK3 genes were studied. 2. Relationships between different gene variants and the treatment efficacy measured by the PANSS. The group of 201 patients with Paranoid Schizophrenia consisted of 95 men (mean age 34) and 105 women (mean age 35). There were no significant differences between the groups according to the studied gender. Males patients had a significantly earlier age of onset but the duration of illness was similar in both gender groups. The patients were treated randomly with perazine, olanzapine or ziprasidone. The control group consist of 230 healthy volunteers ethnically, gender and age matched. Results 1. No differences were found in the allelic distribution in the investigated genes polymorphisms between the whole schizophrenics and the control group. 2. Associations between DAT: A9 allele, DRD2: del 141C allele, DRD2: Taq1A A1 allele, COMT: Met/Met genotype, MAOA: 4VNTR allel (males only) and GRIK3: SER allel with non responding patients were found.

E K Khusnutdinova - One of the best experts on this subject based on the ideXlab platform.

  • the association of polymorphisms in slc18a1 tph1 and reln genes with risk of Paranoid Schizophrenia
    Molecular Biology, 2014
    Co-Authors: Galaktionova Diu, A E Gareeva, E K Khusnutdinova, T V Nasedkina
    Abstract:

    We have developed a biochip for the analysis of polymorphisms in candidate genes for Schizophrenia: DISC1, RELN, ZNF804A, PLXNA2, COMT, SLC18A41, CACNA1C, ANK3, TPH1, PLAA and SNAP-25. Using biochip the allele and genotype frequencies in 198 patients with Schizophrenia and 192 healthy individuals have been obtained. For SLC18A1 polymorphism rs2270641 A>C, the frequencies of A allele (p = 0.007) and AA genotype (p = 0.002) were lower in patients compared with healthy individuals. A significant association was found between AA genotype (p = 0.036) of the TPH1 polymorphism rs1800532 C>A and Schizophrenia. The C allele (p = 0.039) of the RELNpolymorphism rs7341475 C>T were lower in patients with Schizophrenia compared with healthy individuals in a tatar population. Genotype AA of the TPH1 polymorphism rs1800532 C>A were more frequent in patients with Schizophrenia compared with healthy individuals. Ithas been shown that the C allele (p = 0.0001) and GC (p = = 0.0001) genotype of the PLXNA2 polymorphism rs1327175 G>C are associated with the family history in patients with Paranoid Schizophrenia. The obtained data suggest that SLC18A1, TPH1 and RELN gene polymorphisms are associated with the risk of Paranoid Schizophrenia.

  • Association of SLC18A1, TPH1, and RELN gene polymorphisms with risk of Paranoid Schizophrenia
    Molecular Biology, 2014
    Co-Authors: D. Yu. Galaktionova, A E Gareeva, E K Khusnutdinova, T V Nasedkina
    Abstract:

    A biochip was developed to examine the polymorphisms of genes associated with Schizophrenia risk, including DISC1, RELN, ZNF804A, PLXNA2, COMT, SLC18A1, CACNA1C, ANK2, TPH1, PLAA , and SNAP-25 . Allele and genotype frequencies of the genes were determined in 198 schizophrenics and 192 healthy subjects from Bashkortostan (ethnic Russians and Tatars). The frequencies of allele A ( p = 0.007) and genotype AA ( p = 0.002) of the rs2270641 A>C polymorphism of SLC18A1 in the patients with Paranoid Schizophrenia was lower than in the healthy subjects. The frequency of genotype AA of the rs1800532 C>A polymorphism of TPH1 in the schizophrenics was higher than in the healthy subjects ( p = 0.036). Compared with the healthy subjects, the ethnic Tatar patients with Paranoid Schizophrenia had a lower frequency of allele C of the rs7341475 C>T polymorphism of RELN ( p = 0.039) and a higher frequency of genotype AA of the rs1800532 C>A polymorphism of TPH1 ( p = 0.019, OR = 2.52, CI 1.18-5.38). The frequency of allele C ( p = 0.0001) and genotype GC ( p = 0.0001) of the rs1327175 G>C polymorphism of PLXNA2 was elevated in the patients with a family history of Paranoid Schizophrenia. Based on the results, the SLC18A1, TPH1 , and RELN polymorphisms were associated with risk of Schizophrenia.

  • polymorphism of rgs2 gene as genetic marker of Schizophrenia risk and pharmacogenetic markers of the efficiency of typical neuroleptics
    Molecular Biology, 2013
    Co-Authors: A E Gareeva, E K Khusnutdinova, D F Zakirov, R G Valinurov
    Abstract:

    Schizophrenia affects about 1% of the general population. The group of RGS genes that regulate the signaling activity of G protein and modulate signal transduction by the neurotransmitter receptors involved in the pathogenesis of Schizophrenia is currently under active investigation. The association of polymorphism in the RGS2 gene with the occurrence of extrapyramidal disorders induced by neuroleptics was demonstrated previously. The present work involved the analysis of DNA from 258 patients with Paranoid Schizophrenia and 263 healthy blood donors resident in the Republic of Bashkortostan and belonging to Russian and Tatar ethnic groups. Genetic markers of increased risk of Paranoid Schizophrenia, namely, the genotype RGS2*G/*G (rs2746071) in Russians (p = 0.001, OR = 4.08) and Tatars (p = 0.000; OR = 4.88), the allele RGS2*G (rs2746071) in Russians (p = 0.00003, OR = 2.37) and Tatars (p = 0.000; OR = 2.51), as well as genetic markers associated with reduced disease risk, were identified. Moreover, genetic markers associated with increased risk of neuroleptic parkinsonism in Russian patients with Paranoid Schizophrenia treated with the typical antipsychotic haloperidol (RGS2*T/*T (rs2746073), RGS2*C/*C (rs4606), and RGS2*A/*A (rs2746071)) and genetic markers of efficient haloperidol therapy in Tatars were identified. The results are consistent with those obtained previously and support the hypothesis concerning the association of RGS2 gene polymorphisms with the risk of extrapyramidal syndrome development during haloperidol therapy and their involvement in the etiology and pathogenesis of Schizophrenia.

  • association polymorphic variants of grin2b gene with Paranoid Schizophrenia and response to typical neuroleptics in russians and tatars from bashkortostan republic
    Russian Journal of Genetics, 2013
    Co-Authors: A E Gareeva, E K Khusnutdinova, D F Zakirov
    Abstract:

    An analysis of the association of Paranoid Schizophrenia seeking with polymorphic variants of GRIN2B was performed in order to identify genetic risk factors of disease development and genetic markers of the response to therapy by neuroleptics in Russian and Tatar patients from Bashkortostan Republic (BR). In the course of the analysis, we revealed the following: (1) genetic markers of increased risk of developing Paranoid Schizophrenia in various ethnic groups, including, in Tatars, the GRIN2B*T/*T genotype (p = 0.003; OR = 2.33) and GRIN2B*T allele (p = 0.001; OR = 2.36), rs1805247; in Russians, the GRIN2B*T/*T genotype (p = 0.038; OR = 2.12) and GRIN2B*T allele (p = 0.028; OR = 2.03), rs1805247, genotype GRIN2B*A/*A (p = 0.042; OR = 2.12), rs1805476; (2) genetic markers of the reduced risk of developing Paranoid Schizophrenia; (3) genetic markers of therapy response and the risk of side effects development during neuroleptics (haloperidol) treatment in Bashkortostan. The significant interethnic diversity of genetic factors related to the risk of this disease development was noted.